TWI241193B - Human interferon-beta formulations - Google Patents

Human interferon-beta formulations Download PDF

Info

Publication number
TWI241193B
TWI241193B TW091115171A TW91115171A TWI241193B TW I241193 B TWI241193 B TW I241193B TW 091115171 A TW091115171 A TW 091115171A TW 91115171 A TW91115171 A TW 91115171A TW I241193 B TWI241193 B TW I241193B
Authority
TW
Taiwan
Prior art keywords
ifn
pharmaceutical composition
item
patent application
composition according
Prior art date
Application number
TW091115171A
Other languages
English (en)
Chinese (zh)
Inventor
Michael Mccaman
Susanne Ottoboni
Erno Pungor
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of TWI241193B publication Critical patent/TWI241193B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TW091115171A 2001-07-09 2002-07-09 Human interferon-beta formulations TWI241193B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30339501P 2001-07-09 2001-07-09

Publications (1)

Publication Number Publication Date
TWI241193B true TWI241193B (en) 2005-10-11

Family

ID=23171889

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091115171A TWI241193B (en) 2001-07-09 2002-07-09 Human interferon-beta formulations

Country Status (7)

Country Link
US (2) US20030118548A1 (cg-RX-API-DMAC7.html)
JP (1) JP2004538275A (cg-RX-API-DMAC7.html)
AR (1) AR034749A1 (cg-RX-API-DMAC7.html)
PE (1) PE20030303A1 (cg-RX-API-DMAC7.html)
TW (1) TWI241193B (cg-RX-API-DMAC7.html)
UY (1) UY27373A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003006053A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
US20050008616A1 (en) * 2003-07-11 2005-01-13 Schering Aktiengesellschaft Recombinant human interferon-beta-1b polypeptides
JPWO2006033453A1 (ja) * 2004-09-22 2008-05-15 学校法人順天堂 インターフェロン作用物質の活性増強剤
DE602005011321D1 (de) * 2004-11-10 2009-01-08 Novartis Vaccines & Diagnostic Deamidiertes interferon-beta
DOP2006000117A (es) * 2005-05-19 2007-11-30 Schering Ag Terapia génica de interferon-beta usando un sistema mejorado de expresión regulada
UY29544A1 (es) * 2005-05-19 2006-12-29 Schering Ag Tratamiento de enfermedades usando un sistema mejorado de expresión regulada
US20080076729A1 (en) * 2005-05-19 2008-03-27 Schering Aktiengesellachaft Interferon-beta gene therapy using an improved, regulated expression system
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
AU2006275800A1 (en) * 2005-07-29 2007-02-08 Novartis Ag Method and system for in vitro protein folding

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7404589A (nl) * 1974-04-03 1975-10-07 Stichting Rega V Z W Werkwijze voor het stabiliseren van interferon.
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4289689A (en) * 1980-03-14 1981-09-15 Hoffmann-La Roche Inc. Preparation of homogeneous human fibroblast interferon
DE2943016C2 (de) * 1979-10-24 1984-09-06 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Verfahren zur Reinigung von Interferon
JPS5651995A (en) * 1979-10-05 1981-05-09 Green Cross Corp:The Preparation of interferon
NL7907791A (nl) * 1979-10-23 1981-04-27 Stichting Rega V Z W Werkwijze voor het zuiveren van interferon.
US4315852A (en) * 1980-11-26 1982-02-16 Schering Corporation Extraction of interferon from bacteria
JPS5821691A (ja) * 1981-07-29 1983-02-08 Mochida Pharmaceut Co Ltd α−及びβ−インタ−フェロンの精製方法
EP0082481B2 (en) * 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
US4450103A (en) * 1982-03-01 1984-05-22 Cetus Corporation Process for recovering human IFN-β from a transformed microorganism
AU1234383A (en) * 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
US5643566A (en) * 1982-09-23 1997-07-01 Cetus Corporation Formulation processes for lipophilic proteins
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
IL90047A (en) * 1982-10-19 1992-12-01 Cetus Oncology Corp Cysteine-depleted biologically active muteins other than interferon - '
US4485017A (en) * 1982-12-22 1984-11-27 Cetus Corporation Isolation of human interferon by immunosorbent and high performance liquid chromatography
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
US4643566A (en) * 1984-07-20 1987-02-17 Canon Kabushiki Kaisha Particle analyzing apparatus
DE3628468A1 (de) * 1986-08-21 1988-03-03 Thomae Gmbh Dr K Neue applikationsformen fuer (alpha)-interferone
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
FR2687843A1 (fr) * 1992-02-24 1993-08-27 Motorola Semiconducteurs Transistor bipolaire lateral pnp et procede de fabrication.
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
JP3466765B2 (ja) * 1994-07-27 2003-11-17 キッコーマン株式会社 ビオチン化ホタルルシフェラーゼ、ビオチン化ホタルルシフェラーゼ遺伝子、新規な組み換え体dna、ビオチン化ホタルルシフェラーゼの製造法及び生物発光分析法
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5814485A (en) * 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
DE69729880T3 (de) * 1996-12-24 2012-05-10 Biogen Idec Ma Inc. Stabile flüssige interferon-zubereitungen
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta

Also Published As

Publication number Publication date
AR034749A1 (es) 2004-03-17
JP2004538275A (ja) 2004-12-24
US20030118548A1 (en) 2003-06-26
US20050163752A1 (en) 2005-07-28
WO2003006053A1 (en) 2003-01-23
UY27373A1 (es) 2003-02-28
PE20030303A1 (es) 2003-06-21

Similar Documents

Publication Publication Date Title
KR100799402B1 (ko) 안정화된 인터루킨 2
US5981485A (en) Human growth hormone aqueous formulation
CA2337745C (en) Human growth hormone aqueous formulation
US5919443A (en) Stable lyophilized pharmaceutical preparations of G-CSF
US5763394A (en) Human growth hormone aqueous formulation
US20210252105A1 (en) VEGF Antagonist Formulations
KR102720834B1 (ko) Il-15 단백질 복합체 약학 조성물 및 이의 용도
WO2001049314A2 (en) Glp-2 formulations
JP3829991B2 (ja) Hgh含有医薬組成物
EP0364491A1 (en) Stabilized formulations of gamma interferons
JP3714951B2 (ja) Il−6含有薬剤組成物
EP0391444A2 (en) Interleukin-1 Formulation
ZA200407028B (en) Lyophilised preparation comprising immunocytokines.
US20030118548A1 (en) Human interferon-beta formulations
KR900004799B1 (ko) 안정한 감마 인터페론 제제 및 이의 제조방법
US6479048B2 (en) Water-soluble dry compositions
JPWO2000000221A1 (ja) 水溶性乾燥組成物
US5534251A (en) Stabilized il-1α medicinal composition
JP2004538275A5 (cg-RX-API-DMAC7.html)
AU629549B2 (en) Homogeneous dimeric m-csf and storage stable formulations thereof
CN116685309A (zh) 改善的冻干制剂
JP2005232177A (ja) Hgh含有医薬組成物
MXPA03008545A (es) Composiciones farmaceuticas que contienen la hormona humana del crecimiento.

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees